Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.
about
Current research on pharmacologic and regenerative therapies for osteoarthritisOn the predictive utility of animal models of osteoarthritisGenetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug TargetsMatrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switchCCN family member 2/connective tissue growth factor (CCN2/CTGF) has anti-aging effects that protect articular cartilage from age-related degenerative changesDisease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation.Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development.Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis.Matrix metalloproteinase-13 predominates over matrix metalloproteinase-8 as the functional interstitial collagenase in mouse atheromata.The role of microRNAs in the pathogenesis of MMPi-induced skin fibrodysplasia.Responsiveness to change and reliability of measurement of radiographic joint space width in osteoarthritis of the knee: a systematic review.Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis.Bio-enhanced repair of the anterior cruciate ligamentSample Size Calculations for Detecting Disease-Modifying Osteoarthritis Drug Effects on Knee Replacement Incidence in Clinical Trials: Data From the Osteoarthritis Initiative.Matrix Metalloproteinase-13 as a Target for Suppressing Corneal Ulceration Caused by Pseudomonas aeruginosa Infection.Biologic basis of osteoarthritis: state of the evidenceAssessment of potential cross-reactivity of human endogenous matrix metalloproteinases with collagenase Clostridium histolyticum antibodies in human sera obtained from patients with Dupuytren's contracture.New findings in osteoarthritis pathogenesis: therapeutic implications.Inhibition of matrix metalloproteinases enhances in vitro repair of the meniscusMitogen-activated protein kinases as therapeutic targets in osteoarthritis.Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism.Identification of progressors in osteoarthritis by combining biochemical and MRI-based markersBiochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.Application of biochemical markers in development of drugs for treatment of osteoarthritis.The role of matrix metalloproteinases in cystic fibrosis lung disease.A review of translational animal models for knee osteoarthritis.Functional articular cartilage repair: here, near, or is the best approach not yet clear?Involvement of the endocannabinoid system in osteoarthritis pain.Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).Inhibition of aggrecanases as a therapeutic strategy in osteoarthritis.Emerging drugs for the treatment of knee osteoarthritis.Investigational drugs for the treatment of osteoarthritis.Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironmentRandomized controlled studies on the efficacy of antiarthritic agents in inhibiting cartilage degeneration and pain associated with progression of osteoarthritis in the rat.An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease.The quest for the Holy Grail: a disease-modifying osteoarthritis drug.A selective inhibition of c-Fos/activator protein-1 as a potential therapeutic target for intervertebral disc degeneration and associated pain.Current status and future prospects for disease modification in osteoarthritis.
P2860
Q26766598-B8F7F558-B146-4294-ACDC-756824806456Q26781301-0B9F7667-DEF1-44A2-B0F7-22B7089F790CQ26822238-29688897-10B9-4ED8-8477-C4DDB5DD3E00Q26849388-E4FA7073-841A-4640-8F92-8AE8A32D989CQ27309875-06407333-68AC-4407-9DCC-1CC96485D481Q30588700-B03C88C5-9AD0-4A5E-AE04-B22153A9C24CQ33660754-3C3F9E00-619F-44C4-BE0D-2DD4C85B20FFQ33706862-7E27F262-2172-4F53-A404-0B75006D840EQ33880198-4D241550-C766-4B05-9E83-8BC1452842C2Q34009051-CC9675D7-25AC-4224-911E-9F5EC12FAF31Q34728974-4138F7C5-F3C8-4A80-9BC8-E79B2EF28908Q34984813-A5012232-6C60-45EE-AD95-CFDAAA72E06FQ35433466-58E71E21-34B8-46D5-9633-1EC8D30104D0Q35588999-21B5326C-9F09-4572-9230-1853BC7936BEQ35757914-7E5454E2-7DEC-420D-9DFA-44DF16EF8EDEQ35784609-61341F8B-9B15-4555-BB78-564D9980F0AEQ35821610-4DCFC68A-ABD3-4A87-ADB3-50C7EA9FC86EQ35867209-A35733E7-679E-4CAD-9E65-7607285F62FFQ36515489-C77611EC-90CE-4CDE-AE9F-67C83D9940CAQ37171756-D772EF1D-A156-4447-B0F4-1A0DF633602EQ37242365-FF0F1EF7-C05B-4106-B365-8D50D74122EBQ37331102-2EA05BAF-A614-4BC1-BFA9-D802676537DAQ37350908-08CE98B9-2BF6-4C45-AC7D-838930FBA8C4Q37462448-76F95D6E-1AED-49DA-AD59-0D19D6C3B415Q37677789-6C555613-E94B-429B-BBE2-7D57F1773193Q37828316-09B197DA-7848-4E99-9CFF-B5C5487AAFFEQ38074652-1CFE7D3E-8369-42BB-B42A-D77060D7F6B0Q38090916-B17B909C-4978-45D0-ABDB-A6EBEF8A97A6Q38185076-F2CCAF49-9C1A-49B0-AEE6-F1946BB5A66DQ38237471-8ABC66B7-C2B0-4FA3-B375-873FF0758095Q38261368-E0840295-71A9-4058-AD8C-15A902E738CCQ38417521-2ECB6CA1-32E8-40B3-B64A-32E61CDB7C31Q38597565-00FF82DE-4D4C-4289-931D-CF82134D7CC3Q38722186-7FAA38C0-CA7C-43B1-A0E0-4447B96DD4A4Q38726989-F74025A0-DAE3-4477-A77C-AA30CA55E0BFQ38800946-D2346018-A213-48F6-94B4-6B44E25EE134Q38871811-15D5ADB4-1A94-43E2-9114-9DF44AB21B59Q43049843-28AD73DB-FC0F-4791-BEFD-7236342E0B61Q47109791-0576BFE6-B569-4448-B8E4-F355BC799675Q47570656-1BD978B0-BF8F-4564-9DA6-8BB7C975B763
P2860
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Development of musculoskeletal ...... ind, placebo-controlled study.
@ast
Development of musculoskeletal ...... ind, placebo-controlled study.
@en
type
label
Development of musculoskeletal ...... ind, placebo-controlled study.
@ast
Development of musculoskeletal ...... ind, placebo-controlled study.
@en
prefLabel
Development of musculoskeletal ...... ind, placebo-controlled study.
@ast
Development of musculoskeletal ...... ind, placebo-controlled study.
@en
P2093
P2860
P356
P1476
Development of musculoskeletal ...... ind, placebo-controlled study.
@en
P2093
Chris Buckland-Wright
Gary A Cline
Géza Bálint
John Beary
Karen Stoner
Piotr Krzeski
Robert Lyon
Tim D Spector
William S Aronstein
P2860
P2888
P356
10.1186/AR2315
P577
2007-01-01T00:00:00Z
P5875
P6179
1050991406